Almonertinib clinical trials
Almonertinib is named as an intervention in 20 current clinical trials in our China and Taiwan registers. 10 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Jiangsu Hansoh Pharmaceutical Co., Ltd (3). The most-studied condition is Non-small Cell Lung Cancer.
How Almonertinib works
All drug targets →- Epidermal growth factor receptor erbB1 inhibitor InhibitorTarget: EGFR epidermal growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Lung cancerPhase 2/3
- Leptomeningeal metastasisPhase 2
- Squamous cell carcinomaPhase 2
- CancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4761468, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11136, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Almonertinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Almonertinib
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Almonertinib
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Non-small Cell Lung Cancer | 5 |
| Non Small Cell Lung Cancer | 2 |
| Non-Small Cell Lung Cancer | 2 |
| Lung Cancer | 2 |
| EGFR Gene Mutation | 1 |
| Advanced Non-small Cell Lung Cancer | 1 |
| Non-small Cell Lung Carcinoma | 1 |
| Non-Squamous Non-Small Cell Lung Cancer | 1 |
| Non-small Cell Lung Cancer Stage III | 1 |
| Non-small Cell Lung Cancer Metastatic | 1 |
| Rare Tumor | 1 |
| EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor | 1 |
| Brain Metastases | 1 |
| Radiotherapy | 1 |
| EGFR Activating Mutation | 1 |
| Lung Adenocarcinoma Metastatic | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 19 | 9 |
| Clinical trials in Taiwan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Almonertinib trials
How many clinical trials are testing Almonertinib?
20 current trials in our China and Taiwan registers name Almonertinib (also registered as HS-10296) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Almonertinib trials recruiting patients?
Yes. 10 of the 20 trials are recruiting: 9 with sites in China and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Almonertinib clinical trials?
Jiangsu Hansoh Pharmaceutical Co., Ltd (3), Hansoh BioMedical R&D Company (2), Sun Yat-sen University (2) and Suzhou Suncadia Biopharmaceuticals Co., Ltd (2), among 15 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Almonertinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Almonertinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Almonertinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.